Nasdaq:ENTA
ENANTA PHARMACEUTICALS INC
Enanta Pharmaceuticals is an oncology-focused biotech developer advancing a pipeline of novel antibody-drug conjugates for solid tumor treatments.
Key Metrics
Investment Thesis
Bull Case
Investors might consider Enanta for its novel ADC platform which represents a high-growth potential if key clinical trials succeed in solidifying its market position. The narrowing net loss trend suggests the company is gaining operational efficiency or optimizing its R&D spend as it moves closer to commercial milestones. Strategic collaborations provide a revenue buffer that could extend the runway for shareholders despite current cash burn.
Bear Case
The company continues to report significant net losses and a large accumulated deficit, indicating a high risk of capital depletion without successful drug approvals or major financing events. Revenue has been declining over the last three years, which is unsustainable for a commercial-stage biotech lacking a proven blockbuster product. High cash burn rates relative to current cash reserves pose a threat to solvency if fundraising markets tighten or clinical setbacks occur.
About ENANTA PHARMACEUTICALS INC
Enanta Pharmaceuticals develops and commercializes oncology therapies, primarily focusing on its proprietary antibody-drug conjugate (ADC) candidate ENA1347. The company targets the global cancer treatment market with a pipeline designed to address unmet medical needs in solid tumors. Financials reflect heavy investment in research and development typical of pre-commercial biotechnology firms.
Analysis
Management Discussion
Recent financial performance shows a narrowing operating loss from -$133.8M in 2023 to -$81.9M in 2025, indicating improved cost management or stabilization of clinical trial spending despite steady revenue decline. Cash flow from operations remains negative at -$19.3M, while the company utilized significant cash from investing activities of $40.3M, likely related to asset sales or strategic divestitures to bolster liquidity. The gross profit margin exists but is offset by substantial operating expenses including R&D of $106.7M and general administration of $43.9M.
Industry Overview
The global oncology sector is rapidly evolving with advanced therapies like antibody-drug conjugates gaining traction against solid tumors, offering substantial growth opportunities for innovative players. However, the industry remains highly competitive and capital intensive, requiring extensive regulatory navigation and clinical validation before achieving profitability. Market dynamics favor companies with differentiated technologies that can overcome existing standard-of-care treatments while managing complex development timelines.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $79.2M | $67.6M | $65.3M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $79.2M | $67.6M | $65.3M |
| Operating Expenses | $216.4M | $189.3M | $150.7M |
| Operating Income | $-137.2M | $-121.7M | $-85.3M |
| R&D | $163.5M | $131.5M | $106.7M |
| G&A | $52.9M | $57.9M | $43.9M |
| Stock-Based Comp | $28.2M | $26.8M | $18.6M |
| D&A | $2.4M | $2.3M | $4.6M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $6.2M | $3.9M | $1.8M |
| Interest Expense | $5.1M | — | — |
| Pre-Tax Income | $-131.0M | $-117.8M | $-83.5M |
| Income Tax | $2.8M | $-1.7M | $-1.7M |
| Continuing Ops | $-133.8M | $-116.0M | $-81.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-133.8M | $-116.0M | $-81.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-133.8M | $-116.0M | $-81.9M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $422.8M | $299.9M | $204.3M |
| Cash & Equivalents | $85.4M | $37.2M | $32.3M |
| Accounts Receivable | $8.6M | $6.6M | $6.9M |
| Prepaid Expenses | $13.3M | $12.4M | $8.6M |
| Other Current Assets | $315.5M | $243.6M | $156.6M |
| Long-Term Assets | $39.5M | $76.8M | $76.4M |
| PP&E (Net) | $11.9M | $32.7M | $35.4M |
| Operating Leases | $22.8M | $40.7M | $37.5M |
| Other LT Assets | $4.8M | $3.5M | $3.5M |
| Total Assets | $462.3M | $376.7M | $280.7M |
| Current Liabilities | $62.8M | $57.5M | $48.6M |
| Accounts Payable | $4.1M | $8.0M | $1.9M |
| Current Leases | $5.3M | $1.5M | $3.1M |
| Other Current Liab | $35.1M | $34.5M | $30.7M |
| Long-Term Liabilities | $182.8M | $190.3M | $167.5M |
| LT Operating Leases | $21.2M | $53.9M | $54.8M |
| Other LT Liab | $161.5M | $136.4M | $112.7M |
| Total Liabilities | $245.5M | $247.8M | $216.0M |
| Shareholders' Equity | $216.7M | $128.8M | $64.7M |
| Retained Earnings | $-207.0M | $-323.0M | $-404.9M |
| AOCI | $-1.2M | $302.0K | $-339.0K |
| Total L&E | $462.3M | $376.7M | $280.7M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-133.8M | $-116.0M | $-81.9M |
| Non-Cash Adjustments | $46.2M | $41.3M | $98.2M |
| Working Capital Changes | $-15.6M | $-4.0M | $-35.6M |
| Cash from Operations | $-103.2M | $-78.8M | $-19.3M |
| Capital Expenditures | $9.1M | $17.9M | $12.9M |
| Cash from Investing | $-53.6M | $58.2M | $40.3M |
| Cash from Financing | $198.1M | $-27.6M | $-26.6M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $41.4M | $-48.2M | $-5.5M |
| Beginning Cash | $48.0M | $89.4M | $41.2M |
| Ending Cash | $89.4M | $41.2M | $35.7M |
Frequently Asked Questions
How does ENANTA PHARMACEUTICALS INC make money?
The company's revenue is derived from product sales, licensing agreements, and collaborations with commercial partners to bring its ADC therapies to market. Current financials show significant costs allocated to research and development as well as general administrative expenses supporting the clinical advancement of its drug candidates.
What are the main risks for ENTA?
The company faces substantial operating losses driven by high research and development expenditures and limited current revenue generation. Regulatory approval uncertainties for its clinical candidates could delay or prevent market entry, impacting future cash flows significantly. The reliance on external funding sources due to negative net income and large retained earnings deficit exposes the firm to capital market volatility risks. Potential commercialization challenges with ADC technologies could result in lower-than-expected sales if competitive therapies emerge.
What is ENTA's competitive advantage?
Enanta leverages a proprietary technology platform for creating antibody-drug conjugates that aim to improve efficacy and reduce toxicity compared to existing chemotherapy agents. The company benefits from strategic partnerships with major pharmaceutical entities that provide funding and commercialization support, reducing direct financial burden on the biotech. A focused pipeline targeting specific solid tumor indications creates a specialized market position within the crowded oncology sector.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.